

Third-generation CAR-NK Cells Targeting CD7

Drug Name	***0163
Description	A novel immunotherapy is human natural killer cells engineered to express a bivalent third generation chimeric antigen receptor (CAR) comprising two anti-CD7 nanobodies. The product is in preclinical development for the treatment of T cell malignancies.
Target	CD7
Drug Modality	CAR-NK Cells
Indication	Cancer
Product Category	Cancer Immunotherapy
Mechanism of Action	Targeting T-Cell Antigen CD7
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.